

## Press release

Göteborg 2015-04-10

### **Getinge announces date of 2015 Q1 report and conference call**

Getinge will issue its Q1 report for 2015 on Monday April 20<sup>th</sup> 2015 at 13:00 CET, followed by a conference call at 15:00 CET, hosted by Alex Myers, CEO, and Ulf Grunander, CFO.

We invite fund managers, analysts and the media to participate in the conference call. Please see below details to join the conference:

Swedish dial in number: +46 (0) 8 5065 3936

UK dial in number: +44 (0) 20 3427 1918

US dial in number: +1 212 444 0896

Participant passcode: 6171008

#### Agenda

14:45 Call in to the conference

15:00 Review of the Q1 report

15:20 Q&A

16:00 End of conference

Two hours after the end of the conference call, a recorded version of the conference can be accessed for 5 working days on the following number:

Sweden: +46 (0) 8 5051 3897

UK: +44 (0) 20 3427 0598

US: +1 347 366 9565

Code: 6171008

During the telephone conference a presentation will be held. To access the presentation, please use this link:

<http://www.livemeeting.com/cc/premconfeurope/join?id=6171008&role=attend&pw=pw5015>

Alternatively enter the Live Meeting site and log into your meeting using the Meeting ID and Password below:

Live Meeting: <https://www.livemeeting.com/cc/premconfeurope/>

Your Name: (Enter your name)

Web Meeting ID: 6171008

Web Meeting Password: pw5015

For more information, please contact:

Kornelia Rasmussen

Head of Group Communications

Phone: +46 (0)10 335 5810

E-mail: [kornelia.rasmussen@getinge.com](mailto:kornelia.rasmussen@getinge.com)

Getinge Group is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, Getinge and Maquet. ArjoHuntleigh focuses on patient mobility and wound management solutions. Getinge provides solutions for infection control within healthcare and contamination prevention within life sciences. Maquet specializes in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care.

The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.